Depatuxizumab mafodotin
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric/humanized hybrid (mouse/human) |
Target | EGFR |
Clinical data | |
Other names | ABT-414 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6624H10228N1728O2052S42 |
Molar mass | 148.3 kDa g·mol−1 |
Depatuxizumab mafodotin (ABT-414) (INN) is an antibody-drug conjugate designed for the treatment of cancer.[1][2] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.[3]
In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme.[4] It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors.[5] Phase I results were presented at ASCO in 2016.[5]
This drug was developed by AbbVie.
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Depatuxizumab Mafodotin, American Medical Association.
- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
- ^ "Antibody-drug conjugates in the spotlight - The Antibody Society". antibodysociety.org. 14 October 2016.
- ^ "Depatuxizumab mafodotin". en.pharmacodia.com.
- ^ a b "Depatuxizumab mafodotin - AbbVie - AdisInsight". adisinsight.springer.com.